OncoBone Therapeutics

Executive Summary

OncoBone Therapeutics is a French virtual contract research organization (CRO) founded in 2017, specializing in preclinical research at the intersection of oncology and bone diseases, with a particular focus on bone metastasis. The company leverages over 20 years of scientific and operational expertise to manage and accelerate preclinical drug development programs for pharmaceutical and biotech clients. Its unique value proposition lies in acting as a third-party project manager, streamlining communication and coordination among various research partners, thereby reducing inefficiencies in drug development. By offering a virtual model, OncoBone provides flexible, cost-effective solutions without the overhead of physical infrastructure, making it an attractive partner for companies seeking to expedite their oncology-bone pipeline. As a virtual CRO, OncoBone Therapeutics is well-positioned to capitalize on the growing demand for specialized preclinical services in oncology and rare bone diseases. The company's deep expertise in bone metastasis—a challenging and underserved area—differentiates it from broader CROs. While still in the pre-clinical stage, OncoBone has the potential to become a key enabler for biopharma companies aiming to advance therapeutics targeting skeletal metastases. Its virtual model and experienced team reduce client risk and accelerate timelines, which could drive repeat business and long-term partnerships. However, as a small, privately held company, its growth depends on securing high-value contracts and maintaining its competitive edge in a crowded CRO market.

Upcoming Catalysts (preview)

• Q3 2026First major client program milestone completion70% success
• 2026Expansion into new therapeutic areas50% success
• TBDStrategic partnership with a large pharma40% success